This handbook is for commissioners, providers and those leading the local transformation of neurology elective care services. It describes what local health and care systems can do to transform neurology elective care services at pace, why this is necessary and
Neurological Alliance report presenting the findings of the 2018/19 National Neurology Patient Experience Survey. The report covers three main themes – accessible, personalised and holistic care and support (which includes social care, mental health and financial security). Overall, the 2018/19
This document sets out a new personalised care approach for those veterans who have a long term physical, mental or neurological health condition or disability.
Supporting guidance for the Community CQUIN applicable for providers of stroke community services. Outlines how to undertake the six month post stroke reviews and record these on SSNAP (the Sentinel Stroke National Audit Porgramme), supporting personalised stroke care and ongoing
This document provides a framework for effectively planning and delivering personalised care in line with the health commitments of the Armed Forces Covenant.
The case for adopting Neuropad to detect preclinical diabetic peripheral neuropathy is not supported by the evidence. Neuropad detects sub-normal sweating in patients with diabetes but the clinical importance of this in current NHS care pathways is poorly defined. There
The technology described in this briefing is The Vest. It is intended to deliver high-frequency chest wall oscillation for clearing airways. The focus of this briefing is its use in adults and children with complex neurological needs, such as cerebral palsy and
The North West has the highest child emergency hospital admission rate for both asthma and epilepsy and the second highest admission rate for diabetes in England. This report details child emergency hospital admission rates, emergency bed day rates and average
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive
Update on enhanced surveillance of potentially iatrogenic CJD exposures; occasional reports related to human prion disease surveys.
A rapid health needs assessment for children and adults with neurodevelopmental conditions including attention deficit hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD). This report includes a review of the literature which details: risk factors, prevalence estimates and a summary
Welsh Assembly Cross Party Group Hospices and Palliative Care report finding people with terminal illnesses and life-limiting conditions in Wales – especially dementia, heart failure and neurological conditions – face a range of barriers in accessing hospice and palliative care.
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are
This report for the MS Society by the Nuffield Trust examines four key areas in the lives and care of people with MS where the potential of data and technology could be harnessed to make a significant difference: Helping people
This policy document outlines the arrangements for funding of treatment for refractory focal onset seizures, associated with tuberous sclerosis complex, for ages 2 years and above.
Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus). The evidence on the safety of unilateral MRI-guided focused ultrasound thalamotomy for
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults. This guidance replaces NICE technology appraisal guidance 32 on beta interferon and glatiramer acetate for the treatment of multiple sclerosis.
These guidelines aim to increase awareness and understanding of CJD and improve social care for people who are affected by it. The guidelines update the previous guidance published in 2003. They reflect the increasing rareness of the disease and the
This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.
The use of Maraviroc to treat Natalizumab-induced PML-IRIS in relation to RRMS currently has an evidence base limited to very small observational studies. This indication and treatment is currently seen as experimental. Based on limited evidence and the lack of